NO20063221L - Fremgangsmate for behandling av matinntak - Google Patents

Fremgangsmate for behandling av matinntak

Info

Publication number
NO20063221L
NO20063221L NO20063221A NO20063221A NO20063221L NO 20063221 L NO20063221 L NO 20063221L NO 20063221 A NO20063221 A NO 20063221A NO 20063221 A NO20063221 A NO 20063221A NO 20063221 L NO20063221 L NO 20063221L
Authority
NO
Norway
Prior art keywords
person
food intake
eating
procedure
obesity
Prior art date
Application number
NO20063221A
Other languages
English (en)
Norwegian (no)
Inventor
Nir Barak
Original Assignee
Mor Research Applic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL16159504A external-priority patent/IL161595A0/xx
Application filed by Mor Research Applic Ltd filed Critical Mor Research Applic Ltd
Publication of NO20063221L publication Critical patent/NO20063221L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20063221A 2004-04-22 2006-07-11 Fremgangsmate for behandling av matinntak NO20063221L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL16159504A IL161595A0 (en) 2004-04-22 2004-04-22 Betahistine as a weight management agent
US67029005P 2005-04-12 2005-04-12
PCT/IL2005/000440 WO2005101979A2 (en) 2004-04-22 2005-04-21 Method of food intake management

Publications (1)

Publication Number Publication Date
NO20063221L true NO20063221L (no) 2006-10-06

Family

ID=35197421

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063221A NO20063221L (no) 2004-04-22 2006-07-11 Fremgangsmate for behandling av matinntak

Country Status (10)

Country Link
US (5) US20060084686A1 (enExample)
EP (1) EP1737454A4 (enExample)
JP (1) JP2007533733A (enExample)
KR (1) KR20060134041A (enExample)
BR (1) BRPI0506807A (enExample)
CA (1) CA2553309A1 (enExample)
EA (1) EA200601414A1 (enExample)
IL (1) IL176793A0 (enExample)
NO (1) NO20063221L (enExample)
WO (1) WO2005101979A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051440A1 (en) * 2004-04-22 2008-02-28 Mor Research Applications Ltd. Compositions for weight management
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
CA2553309A1 (en) * 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US8748419B2 (en) * 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
CN101472476B (zh) * 2006-06-16 2013-10-30 泰拉科斯有限公司 毒蕈碱型受体m1拮抗剂在制备治疗肥胖症的药物中的应用
US20080033019A1 (en) * 2006-08-07 2008-02-07 Duke University Cholesterol lowering drug combination
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) * 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
RU2492858C2 (ru) * 2007-04-11 2013-09-20 Омерос Корпорейшн Композиции и способы профилактики и лечения зависимостей
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
US8586634B2 (en) * 2007-06-15 2013-11-19 University Of Florida Research Foundation, Inc. Therapeutic compounds
WO2009143572A1 (en) 2008-05-27 2009-12-03 The University Of Melbourne Methods of treating mammals with eustachian tube dysfunctions
US20120115778A1 (en) * 2009-07-15 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods of Suppressing Appetite by the Administration of Antagonists of the Serotonin HTR1a or HTR2b Receptors or Inhibitors of TPH2
US20110021507A1 (en) * 2009-07-22 2011-01-27 Theracos, Inc. Inhibiting antipsychotic-induced weight gain
CN102576384A (zh) * 2009-10-13 2012-07-11 雀巢产品技术援助有限公司 用于评估膳食摄入量的系统以及使用的方法
NZ600379A (en) 2009-12-04 2014-05-30 Alkermes Pharma Ireland Ltd Morphinan derivatives for the treatment of drug overdose
US20110143704A1 (en) 2009-12-14 2011-06-16 William Lorentz Specialized dial a chip
SI3446565T1 (sl) 2010-08-23 2024-03-29 Alkermes Pharma Ireland Limited Metode zdravljenja povečanja teže, povzročene z antipsihotiki
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US20140072936A1 (en) * 2012-09-07 2014-03-13 Patrick D. Herron Method of Tracking Consumption and Associated Effects
JP2016519161A (ja) 2013-05-24 2016-06-30 アルカームス ファーマ アイルランド リミテッド モルファン及びモルフィナン類似物及び使用の方法
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
RU2540911C2 (ru) * 2013-06-11 2015-02-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ коррекции синдрома ночной еды у пациентов с тревожно-депрессивными расстройствами
DE102015202695A1 (de) * 2015-02-13 2016-08-18 Carl Zeiss Smt Gmbh Prüfvorrichtung sowie Verfahren zum Prüfen eines Spiegels
MA46778B1 (fr) 2017-02-02 2022-08-31 Otolanum Ag Composition intranasale comprenant de la bétahistine
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
WO2024182465A2 (en) * 2023-02-28 2024-09-06 Alco Therapeutics, Llc Methods for treating obsessive compulsive related disorders, tic disorders and glutamate excitotoxicity related disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1577871A (en) 1976-05-28 1980-10-29 Unimed Inc Prevention of myocardial infarction
JPS55154915A (en) * 1979-05-21 1980-12-02 Jiyan Sadeia Shieruki Medicine mold
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
AU779264B2 (en) 1998-12-23 2005-01-13 G.D. Searle Llc Combinations for cardiovascular indications
DE69939027D1 (de) * 1998-12-23 2008-08-14 Maxim Pharm Inc Synthese von histamin-dihydrochlorid
IT1309591B1 (it) 1999-03-05 2002-01-24 Formenti Farmaceutici Spa Composizioni a rilascio controllato di betaistina.
AU4598400A (en) * 1999-05-19 2000-12-12 Astrazeneca Ab Method of treatment
ATE334659T1 (de) * 2000-03-08 2006-08-15 Awd Pharma Gmbh & Co Kg Pharmazeutische formulierungen enthaltend saccharosefettsäureester zur steuerung der wirkstofffreisetzung
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
AU2002320025A1 (en) 2001-04-11 2002-11-11 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
US20030162824A1 (en) 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
US20040110803A1 (en) 2002-09-13 2004-06-10 Hossein Dovlatabadi Methods and compositions for the use of D-malic acid to decrease serum triglyceride, cholesterol and lipoprotein levels
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
CA2553309A1 (en) * 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
US20080051440A1 (en) * 2004-04-22 2008-02-28 Mor Research Applications Ltd. Compositions for weight management
US20060039867A1 (en) 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders with setiptiline

Also Published As

Publication number Publication date
US7737165B2 (en) 2010-06-15
US20080004324A1 (en) 2008-01-03
BRPI0506807A (pt) 2007-05-29
KR20060134041A (ko) 2006-12-27
WO2005101979A2 (en) 2005-11-03
EA200601414A1 (ru) 2007-02-27
US20080004322A1 (en) 2008-01-03
EP1737454A2 (en) 2007-01-03
JP2007533733A (ja) 2007-11-22
US20060073217A1 (en) 2006-04-06
WO2005101979A3 (en) 2006-07-27
EP1737454A4 (en) 2007-08-08
US20080051439A1 (en) 2008-02-28
IL176793A0 (en) 2006-10-31
US20060084686A1 (en) 2006-04-20
CA2553309A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
NO20063221L (no) Fremgangsmate for behandling av matinntak
WO2006105345A3 (en) Compositions and methods for the control, prevention, and treatment of obesity and eating disorders
WO2007112069A3 (en) Endothelin and endothelin receptor agonists in the treatment of metabolic diseases
GB2441276A (en) Multiple media access control apparatus and method
WO2004110385A3 (en) Modulators of the glucocorticoid receptor and method
WO2006129193A3 (en) Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
Majumder et al. Lactobacillus rhamnosus GG improves skeletal muscle fatigability in a mouse model of hyperhomocysteinemia
WO2006091505A3 (en) Neuropeptide y receptor agonists
Inglis et al. Assessing nutritional and Vitamin D status of postmenopausal obese and osteosarcopenic obese women
EA200970141A1 (ru) Комбинация модафинила и антагониста или обратного агониста рецептора н3
Esler On a low calorie diet, are there separate and discrete effects of negative energy balance and weight loss on blood pressure?
Pan Gains from green cards: Immigrant parents' legal status and children's scholastic achievement
Aguirre‐Fuerte et al. ALTERATIONS IN THE ENDOCANNABINOID SYSTEM IN ASTROCYTES RELATED TO COMMERCIAL SWEETENER INTAKE
CN202698252U (zh) 可调节高度、远近、倾斜角度的电脑桌推拉抽屉
McEniery et al. Mechanisms Underlying Obesity‐Related Hypertension: An Experimental Weight Gain Study in Humans
Lou et al. Corn Peptide Ingestion with Exercise Attenuate Body Fat Mass and Enhance Lean Body Mass in obese rats
Kolev et al. Balance exercises and physical therapy management of vestibular dysfunction–our experience
Skelly et al. Tempol, a SOD‐mimetic, improves rat pharyngeal dilator muscle performance during hyperoxia and hypoxia
MILANI et al. ORAL: ASSESSING THE RELATIONSHIP BETWEEN FOOD INSECURITY & WEIGHT STATUS OF THE ELDERLY APPLYING FACPS-FSSM MEASUREMENT TOOL, ADOPTED FOR IRANIAN ELDERLY
Zheng et al. Enhanced muscle contractility and anti‐fatigue proprieties of CordyMax5
Fu et al. Neither gender nor the menstrual cycle affects sympathetic baroreflex sensitivity during orthostasis in humans
Cui et al. ALTERED TOLL-LIKE RECEPTOR 4 ACTIVATION PLAYS A CRITICAL ROLE IN CYSTITIS PAIN: A MAPP RESEARCH NETWORK ANIMAL MODEL STUDY: PD55-02
Leonardi et al. Functioning and disability in person with epilepsy: evaluating need rehabilitation with ICF
Peñailillo et al. Cryotherapy as Control Delayed Onset Muscle Soreness Treatment: 688: 1: 45 PM–2: 00 PM
Racine et al. The effect of home delivered DASH meals on the diets of older adults with cardiovascular disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application